Novo Ventures
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Seed, Early Stage, Growth, Late Stage
Geographical Focus
United States, United Kingdom, Canada, Germany, Japan, Australia, Singapore, China, India, Brazil, France, Italy, Denmark, Switzerland, Spain, Mexico, South Korea, Netherlands, South Africa, Belgium
Industries Focus
- Healthcare Services
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Regenerative Medicine
- Consumer Health
- Agricultural Biotechnology
- Immuno-Oncology
- Rare Diseases
- Gene Therapy
- Animal Health
- Food and Nutrition
- Environmental Health
Investment Size:
5,000,000 to 50,000,000 USD
Investor Details Founded: 2014
Novo Ventures is the venture capital arm of Novo Holdings A/S, focusing on life sciences investments in Europe and North America. With a presence in Copenhagen, London, San Francisco, and Boston, Novo Ventures is well-positioned in major global life science hubs. Since 2014, the team has facilitated investments of approximately $1.9 billion in 106 companies, achieving successful exits for 68 through IPOs and divestitures.
The firm's investment strategy encompasses a broad spectrum of life science sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services. Novo Ventures supports companies at various stages, from seed to late-stage growth, aiming to advance innovative therapies and technologies that can transform patient care. The team collaborates closely with entrepreneurs and management teams, providing not only capital but also strategic guidance to foster growth and success.
Novo Ventures operates with a long-term investment horizon, emphasizing sustainable value creation and a commitment to improving global health. The firm's approach is characterized by a deep understanding of the life sciences industry, a rigorous investment process, and a dedication to supporting companies that align with its mission to enhance human health and well-being.
Requirements
- Innovative life science companies with strong growth potential
- Alignment with Novo Ventures' focus areas in biotechnology, pharmaceuticals, medical devices, and healthcare services
- Management teams with a clear vision and commitment to advancing patient care
Contact
[Official Website Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Windward Bio AG
- Catalent
- Crystalys Therapeutics
- Subra
- Benchmark Genetics
- AgNext
- AvenCell
- Booster Therapeutics
- Elektrofi
- KIVU BIOSCIENCE
- Stingray Marine Solutions
- Convergent
- Medi Assist
- Route92
- Oxford Nanopore Technologies
- Magenta Medical
- MATR Foods
- Myricx Bio
- Single Use Support
- Sejet Plant Breeding (Sejet)
Mentioned In
-
$24.95
-
$49.95
-
$9.95
-
$39.95
-
$19.95
-
$24.95
-
$99.00
-
$245.00
Claim this Investor
Are you an official representative of Novo Ventures?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim